A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Delestrogen Side Effects, and Drug Interactions - Estradiol valerate
Delestrogen Side Effects, and Drug Interactions - Estradiol valerate
SIDE EFFECTS
See BOXED WARNINGS, WARNINGS,
and PRECAUTIONS.
The following additional adverse reactions have been reported
with estrogens:
1. Genitourinary system
Changes in vaginal bleeding pattern and abnormal withdrawal
bleeding or flow; breakthrough bleeding; spotting; increase in size of uterine
leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical
secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia;
endometrial cancer.
2. Breasts
Tenderness, enlargement, pain, nipple discharge, galactorrhea;
fibrocystic breast changes; breast cancer.
3. Cardiovascular
Deep and superficial venous thrombosis; pulmonary embolism;
thrombophlebitis; myocardial infarction; stroke; increase in blood pressure.
4. Gastrointestinal
Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice;
increased incidence of gallbladder disease; pancreatitis.
5. Skin
Chloasma or melasma, which may persist when drug is discontinued;
erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair;
hirsutism; pruritus, rash.
6. Eyes
Retinal vascular thrombosis; steepening of corneal curvature;
intolerance to contact lenses.
7. Central Nervous System
Headache; migraine; dizziness; mental depression; chorea; nervousness;
mood disturbances; irritability; exacerbation of epilepsy.
8. Miscellaneous
Increase or decrease in weight; reduced carbohydrate tolerance;
aggravation of porphyria; edema; arthalgias; leg cramps; changes in libido;
anaphylactoid/anaphylactic reactions including urticaria and angioedema; hypocalcemia;
exacerbation of asthma; increased triglycerides.
DRUG INTERACTIONS
D. Drug/Laboratory Test Interactions.
1. Accelerated prothrombin time, partial thromboplastin
time, and platelet aggregation time; increased platelet count; increased factors
II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex,
II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa
and antithrombin III, decreased antithrombin III activity; increased levels
of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
2. Increased thyroid-binding globulin (TBG) levels
leading to increased circulating total thyroid hormone levels as measured by
protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay)
or T3 levels by radioimmunoassay. T3 resin uptake is decreased,
reflecting the elevated TBG. Free T4 and free T3 concentrations
are unaltered. Patients on thyroid replacement therapy may require higher doses
of thyroid hormone.
3. Other binding proteins may be elevated in serum
(i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG))
leading to increased circulating corticosteroids and sex steroids, respectively.
Free or biologically active hormone concentrations are unchanged. Other plasma
proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin,
ceruloplasmin).
4. Increased plasma HDL and HDL2 subfraction
concentrations, reduced LDL cholesterol concentration, increased triglycerides
levels.
5. Impaired glucose tolerance.
6. Reduced response to metyrapone test.
top
